170 related articles for article (PubMed ID: 30191954)
1. Therapeutic potency of Wnt signaling antagonists in the pathogenesis of prostate cancer, current status and perspectives.
Pashirzad M; Shafiee M; Khazaei M; Fiuji H; Ryzhikov M; Soleimanpour S; Hesari A; Avan A; Hassanian SM
J Cell Physiol; 2019 Feb; 234(2):1237-1247. PubMed ID: 30191954
[TBL] [Abstract][Full Text] [Related]
2. The WNT/β-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro.
Stakheev D; Taborska P; Strizova Z; Podrazil M; Bartunkova J; Smrz D
Sci Rep; 2019 Mar; 9(1):4761. PubMed ID: 30886380
[TBL] [Abstract][Full Text] [Related]
3. The involvement of noncanonical Wnt signaling in cancers.
Chen Y; Chen Z; Tang Y; Xiao Q
Biomed Pharmacother; 2021 Jan; 133():110946. PubMed ID: 33212376
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Wnt/β-catenin signaling pathway in cancer.
Zhang Y; Wang X
J Hematol Oncol; 2020 Dec; 13(1):165. PubMed ID: 33276800
[TBL] [Abstract][Full Text] [Related]
5. Wnt/beta-catenin pathway: modulating anticancer immune response.
Pai SG; Carneiro BA; Mota JM; Costa R; Leite CA; Barroso-Sousa R; Kaplan JB; Chae YK; Giles FJ
J Hematol Oncol; 2017 May; 10(1):101. PubMed ID: 28476164
[TBL] [Abstract][Full Text] [Related]
6. Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer.
Cui J; Jiang W; Wang S; Wang L; Xie K
Curr Pharm Des; 2012; 18(17):2464-71. PubMed ID: 22372504
[TBL] [Abstract][Full Text] [Related]
7. Wnt/β-catenin signaling contributes to prostate cancer heterogeneity through reciprocal suppression of H3K27 trimethylation.
Wang F; Zhu Y; Wang F; Wang Y; Dong BJ; Wang N; Gao WQ
Biochem Biophys Res Commun; 2020 Jun; 527(1):242-249. PubMed ID: 32446375
[TBL] [Abstract][Full Text] [Related]
8. Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics.
Harb J; Lin PJ; Hao J
Curr Oncol Rep; 2019 Feb; 21(2):12. PubMed ID: 30715618
[TBL] [Abstract][Full Text] [Related]
9. Noncanonical Wnt as a prognostic marker in prostate cancer: "you can't always get what you Wnt".
Fisher RR; Pleskow HM; Bedingfield K; Miyamoto DT
Expert Rev Mol Diagn; 2020 Feb; 20(2):245-254. PubMed ID: 31814454
[No Abstract] [Full Text] [Related]
10. Novel Wnt signaling and other pathway inhibitors in the colorectal cancer genomic landscape era.
Roukos DH; Ziogas DE; Papaloukas C; Baltogiannis G
Future Oncol; 2012 Nov; 8(11):1373-6. PubMed ID: 23148609
[No Abstract] [Full Text] [Related]
11. Secreted Wnt antagonists in leukemia: A road yet to be paved.
Pehlivan M; Çalışkan C; Yüce Z; Sercan HO
Leuk Res; 2018 Jun; 69():24-30. PubMed ID: 29625321
[TBL] [Abstract][Full Text] [Related]
12. Wnt Signaling and Drug Resistance in Cancer.
Zhong Z; Virshup DM
Mol Pharmacol; 2020 Feb; 97(2):72-89. PubMed ID: 31787618
[TBL] [Abstract][Full Text] [Related]
13. [Antagonists of Wnt pathway].
Kinoshita Y; Fukumoto S
Clin Calcium; 2013 Jun; 23(6):817-23. PubMed ID: 23719493
[TBL] [Abstract][Full Text] [Related]
14. Wnt signaling in osteosarcoma.
Lin CH; Ji T; Chen CF; Hoang BH
Adv Exp Med Biol; 2014; 804():33-45. PubMed ID: 24924167
[TBL] [Abstract][Full Text] [Related]
15. Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha.
Jiang YG; Luo Y; He DL; Li X; Zhang LL; Peng T; Li MC; Lin YH
Int J Urol; 2007 Nov; 14(11):1034-9. PubMed ID: 17956532
[TBL] [Abstract][Full Text] [Related]
16. Wnt signaling and prostate cancer.
Robinson DR; Zylstra CR; Williams BO
Curr Drug Targets; 2008 Jul; 9(7):571-80. PubMed ID: 18673243
[TBL] [Abstract][Full Text] [Related]
17. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
18. Diallyl trisulfide inhibits proliferation, invasion and angiogenesis of glioma cells by inactivating Wnt/β-catenin signaling.
Tao Q; Wu C; Xu R; Niu L; Qin J; Liu N; Zhang P; Wang C
Cell Tissue Res; 2017 Dec; 370(3):379-390. PubMed ID: 28815294
[TBL] [Abstract][Full Text] [Related]
19. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
[TBL] [Abstract][Full Text] [Related]
20. Revisiting the role of Wnt/β-catenin signaling in prostate cancer.
Schneider JA; Logan SK
Mol Cell Endocrinol; 2018 Feb; 462(Pt A):3-8. PubMed ID: 28189566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
